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ABSTRACT 
BRENT D. HEHL:  Identifying Genetic Factors Affecting Anthracycline-Induced Cytotoxcity 
(Under the direction of Howard McLeod, PharmD) 
 
The molecular mechanisms responsible for anthracycline-induced cytotoxicity have 
been elusive despite intensive research over the past half century.  Here, hits from a genome-
wide association (GWA) screen seeking to identify genetic factors influencing drug-dose 
response were validated using a shRNA approach.  The initial screen examined the phenotypic 
response of over 500 CHORI patient lymphoblastoid cell lines (LCLs) to the anthracyclines 
daunorubicin, epirubicin, and doxorubicin.  Five candidate genes were identified from statistical 
correlation between intrinsic genomic differences and phenotype variability across the 
population of cell lines. 
Of the 5 candidates selected (ADTRP, CSMD3, FHIT, PELI2, and SLC24A3), stable 
knockdown of PELI2 (and the positive control TOP2A) in LCLs were shown to have a significant 
effect on dose-dependent anthracycline response.  While TOP2A has been previously 
established in the mechanism of anthracycline response, the identification of PELI2 in this 
screen is intriguing given recent work implicating NF-κβ signaling pathways in anthracycline 
response.  These results establish shRNA-mediated gene-knockdown as a means to further 
validate GWA screens in LCLs. 
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CHAPTER 1 
BACKGROUND 
 
While the promise of genetic screening and personalized medicine has yet to be fully 
realized in the post-Human Genome Project world [1], a better understanding of the influence 
of individual genetic variation on established methods of pharmacological intervention will 
positively affect current standards of care [2].  Tools that model genetic diversity, such as 
lymphoblastoid cell lines (LCLs), have proven effective in identifying loci affecting drug-response 
phenotypes [3].  This study employs the advantages (natural genomic variation and 
experimentally tractability) of the LCL system in efforts to better understand genes involved in 
the mechanism of anthracycline action.  
Anthracyclines were first discovered in the early 1960s [4] and are among the most 
potent chemotherapeutics ever developed [5].  As a conventional cytotoxic cancer treatment, 
undesirable side effects are a key concern limiting their medical utility, with severe 
cardiotoxicity being recognized early in clinical development [6].  Tumor resistance [7] is also a 
clinical concern but the development and utilization of various combination drug therapy 
cocktails [5] have reduced its occurrence.  By the early 1990s, an estimated 2000 analogues had 
been synthesized, with none more effective than the first anthracyclines, daunorubicin and 
doxorubicin [6].  The few derivatives in clinical use (epirubicin [8], idarubicin [9], and 
mitoxantrone [10]) may reduce toxicity and improve patient outcomes, but conflicting reports 
exist [11].  Balancing efforts to clarify the mechanism of action, reduce cardiotoxicity, and 
improve clinical effectiveness have long been a mainstay of anthracycline research [6].   
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Anthracycline antineoplastic, cardiotoxic, and drug resistance mechanism(s) are 
vigorously debated [11, 12].  Intriguingly, several different pathways are thought to meditate 
these effects (Figure 1), promising the hope of developing more effective and less toxic 
analogues.  Anthracycline-DNA intercalation and damage induce cancer cell apoptosis, while in 
the heart, iron-mediated free radical generation has been shown to disrupt mitochondria to 
deleterious effect.  Proposed resistance mechanisms include induction of drug metabolizing 
enzymes and transporters, as well as modulation of DNA damage and oxidative stress pathways 
[13]. 
Figure 1: Cellular factors affecting doxorubicin (DOX) response. 
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Figure 1: Continued 
Rather than a single molecular target, a diverse set of cellular factors (transporters, oxidative signaling components, 
interactions with the proteasome, and DNA-repair/signaling proteins) contribute to doxorubicin’s antineoplastic 
efficacy.  It has been shown that tumors that establish chemo-resistance to DOX both modulate expression of and 
accumulate mutations within these pathways. 
 
Antitumor activity:  Early work in the 1970s revealed that anthracyclines bind nucleic 
acid and inhibit DNA synthesis [14], as well as induce protein-associated dsDNA breaks [15].  
Topoisomerase II (TOP2A) [16, 17] was later discovered to mediate anthracycline-induced DNA 
lesions and activate DNA-damage apoptotic pathways, although the contribution of these 
pathways in the antitumor response isn’t entirely clear in context of heterogeneous 
malignancies [18, 19].  Studies have also investigated the sequence specificity of anthracycline-
DNA binding, which causes genotoxic stress by blocking transcription factor binding [20, 21].  
Interestingly, anthracyclines also inhibit the proteasome, affecting protein turnover and cellular 
signaling [22].  Albeit controversial [12], the role of free radical formation also plays a role in 
apoptotic (nuclear signaling) and cardiotoxic (mitochondrial disruption) effects.   
Cardiotoxicity:  Two forms of cardiotoxicity manifest in response to anthracycline 
treatment.  The relatively rare (1%) acute onset cardiotoxicity can be managed in the clinic and 
is mostly reversible, while the more serious chronic cardiotoxicity is a fairly grave prognosis.  
Intriguingly, these chronic side effects can also become manifest several years after the initial 
treatment.  To date, restricting patients to a cumulative lifetime dose has been the most 
successful measure in mitigating cardiotoxicity [23].  The iron modulator dexrazoxane and 
methods to modulate anthracycline pharmacokinetics, such as liposomal formulations and 
slower infusions, have seen limited benefit [11] in mitigating this side effect. 
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Specific characteristics of cardiomyocytes related to oxidative capacity have been 
proposed to explain their susceptibility to anthracycline stress [24, 25].  In comparison to other 
tissues, the heart contains relatively low concentrations of regenerative antioxidants such as 
glutathione and catalase, and higher amounts of iron, an important metal species in the 
generation of reactive oxygen species.  Anthracycline metabolites (oxidative stressors) have a 
long half-life and seem to preferentially accumulate in heart tissue [26].  As systemic blood 
levels of antioxidants also diminish upon anthracycline treatment, it is tempting to speculate 
that the heart may be exposed to a greater oxidative stress that it, as particularly susceptible to 
free radical damage, can reasonably accommodate.  Many animal studies investigating the 
cardio-protective effects of various antioxidants in context of anthracycline treatment 
corroborate this line of reasoning, while similar protocols in human clinical trials have been 
disappointing in their inability to demonstrate any cardio-protective benefit [24]. 
 
Anthracycline Family 
In the body of work described here, three members of the anthracycline family were 
examined: daunorubicin, doxorubicin, and epirubicin. 
Daunorubicin [6]:  Daunorubicin (DNR) was independently discovered by both Di Marco 
and Dubost in the late 1950s and early 1960s.  A natural product from the soil microbe 
Streptomyces peucetius, it saw great use in the 70s and 80s against a wide variety of neoplasms.  
Other treatments have been developed against many of its original indications, but today it is 
still used upon occasion against acute myeloid and lymphocytic leukemias [27].   
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Doxorubicin [6]:  Doxorubicin is very similar in chemical structure to DNR and can also 
be considered a natural product, however it was isolated from a mutagenized strain of 
Streptomyces.  Approved after only six years of clinical testing, doxorubicin (DOX) is the most 
potent anthracycline and mainly used in highly effective liposomal preparations (Doxil™) against 
breast, small-cell lung, and ovarian carcinomas, and many sarcomas as well.  Skin, colon and 
renal cancer are some of the few cancer types that do not respond to doxorubicin (DOX).  Due 
to its incorporation into drug cocktails targeting a wide number of neoplasms, annual sales are 
currently maintained over $500 million, nearly fifty years after its identification [28].  
Epirubicin [6]:  Epirubicin (EPI) was synthesized in the 1970s and shown to have similar 
efficacy as compared to DOX in animal models, but with a modified pharmacodynamic profile 
[29].  The small chemical difference from the parent daunorubicin molecule leads to faster 
elimination from the body, allowing EPI can be used at nearly twice the cumulative lifetime dose 
than DOX.  While clinicians still adhere to a limited lifetime dosage to limit the risk of chronic 
cardiotoxicity, the increased clearance characteristics allow for more aggressive dosage 
regimens and improved response rates [30].  Myleosuppression becomes a concern under such 
conditions, but can be clinically managed more effectively than chronic cardiotoxicity.  
Epirubicin is mainly employed against breast, ovarian, stomach, and lung cancers, as well as 
certain lymphomas.   
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Figure 2: Anthracycline Chemical Structures 
 
The three anthracyclines in our screen are remarkably similar, with the minor chemical differences from DNR 
highlighted in red. 
 
Genome-Wide Association (GWA) studies 
Genome-wide approaches [31-34] have been developed to interrogate drug function, 
examine biological mechanisms, and identify molecular targets.  A more clear understanding of 
such information enables the development of next-generation pharmaceuticals that minimize 
underlying toxicity, resistance, and/or boost efficacy.   
Lymphoblastoid cell lines (LCLs) approximately model healthy human cells [3] and offer 
certain advantages over comparative studies in yeast [31] and human cancer cell models [32].  
>500 CHORI (Children’s Hospital of Oakland Research Institute) LCLs [35] were previously both 
phenotyped for anthracycline (DNR, DOX, EPI) dose-response and profiled across the genome at 
single nucleotide polymorphism (SNP) resolution.   Here, SNPs arising from the screen as 
effectors of drug response were identified and further refined into a candidate gene list for 
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further validation.  A modified dose-response assay utilizing shRNA gene knockdown and 
anthracycline sensitive and resistant CHORI cell lines was developed and employed to determine 
if candidate gene knockdown would affect cell viability in response to anthracycline exposure 
and if so, if the effect was consistent across the entire drug class.  Of the five candidate genes 
interrogated, the results of this study indicate knockdown of PELI2 sensitizes CHORI cells to all 
three anthracyclines in a consistent manner.  This result is consistent with recent findings 
implicating NF-ᴋβ signaling in anthracycline pharmacology. 
 
 
  
 
 
CHAPTER 2 
MATERIALS AND METHODS 
 
Cell Culture 
CHORI (Children’s Hospital of Oakland Research Institute) generously donated EBV-
transformed lymphoblastoid cell lines [35].  These CHORI lines were cultured in Roswell Park 
Memorial Institute (RPMI) medium (Invitrogen) supplemented with 15% fetal bovine serum 
(Sigma) and 100U/mL Penicillin and Streptomycin (Cellgro).     
For stable cell line selection, Puromycin was added to the media at a final concentration 
of 1.0 µg/mL.  Cell cultures were incubated at 37ºC and 5% CO2 in a humidified incubator.  A Z1 
Coulter Particle Counter (Beckman Coulter) was used to count cell concentrations.  Cell lines 
were frozen into aliquots for use in future experiments and a new vial was used for each of the 
three replicates performed in this study. 
 
Production of Lentiviral Particles 
pLKO.1 shRNA bacterial stocks were obtained from OpenBiosystems and TRC1 shRNA  
libraries were constructed at the University of North Carolina-Chapel Hill Lenti-shRNA core 
facility.  For each gene, 5 distinct shRNA plasmids were obtained, as detailed in Supplemental 
Table 1.  Bacterial stocks were inoculated in Terrific Broth medium (MP Biomedicals) containing 
100µg/mL of Carbenicillin (Invitrogen) and DNA isolated via MidiPrep kits (Qiagen).  
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For each transfected plasmid, 1x106 HEK-293T cells were seeded into a 6 cm cell culture 
dish overnight.  The media was replaced with 5 mL antibiotic-free media for 8 hours.  The 
transfection was then performed using 1 µg of each pLKO.1 shRNA plasmid with 750 ng of 
psPAX2 packaging plasmid and 250 ng pMD2.G envelope plasmid in 20 µl of serum-free OPTI-
MEM (Invitrogen). The plasmid DNA mixture was mixed with 80 µl of OPTI-MEM containing 6 µl 
FuGENE 6 (Promega) and incubated for 30 minutes.  The mixture was then added to the HEK-
293T cells for 18 hrs, after which media was replaced with 5 mL fresh DMEM.  The virus-
containing media was collected and stored at 4°C 24h and 48h post-transfection, with 5 
mL fresh media added to the cells after collection.  
 
Transduction of Cell Lines 
Five pools per each targeted gene of virus-containing media were combined and added 
to CHORI cell lines.  One mL of transduction particle supernatant was added to 1 mL (1x106 cells) 
of each of the CHORI cell lines.  Media was replaced after 24 hours and 1 µg/mL of puromycin 
was added 48 hrs post-infection to select for transduced cells.  Cells were under selection for 1 
week with fresh puromycin added at day 4. 
 
Knockdown Quantification 
Western blots were performed using cell lysates to determine the extent of knockdown.  
Approximately 2 x 106 cells were lysed in RIPA buffer (Dulbecco’s PBS, 0.1% Sodium Dodecyl 
Sulfate, 0.5% Sodium Deoxycholate, and 1% Igepal NP-40 supplemented with 1 mM PMSF, 1x 
complete protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN), and 1x Phosphatase 
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Inhibitor Cocktail 2 (Sigma, St. Louis, MO).  An aliquot was used for protein quantitation 
determination using the BCA protein assay kit (Pierce Technology, Inc., St. Louis, MO).  The 
remaining sample was mixed with 0.5 vol of 3x SDS sample buffer (1x equals 31.25 mM Tris-
HCl  (pH 6.8), 2% SDS, 5% 2-mercaptoethanol, 10% sucrose, and 0.005% bromophenol blue) and 
heated for 5 minutes at approximately 95oC.  Equivalent protein amounts were run on SDS-PAGE 
in Tris/glycine/SDS buffer using 10% acrylamide gels.  Resolved proteins were then transferred 
to PVDF membranes.  The blots were blocked using a 5% solution of nonfat dry milk in 20mM 
Tris-HCl, pH7.4, 140mM NaCl, 0.1% Tween 20 and exposed to antibodies in the same 
buffer.  Rabbit anti-human TOP2 (kind gift of Dr. Jack Griffith) was used to detect TOP2.  Anti-β-
actin (Sigma) was used as a loading control.  Horseradish peroxidase-conjugated secondary 
antibodies were used as needed with ECL detection reagent (GE Healthcare Bio-Sciences Corp.) 
to visualize immunoreactive bands.  Protein levels were quantified from autoradiographs 
scanned with an Agfa Duoscan T2500 scanner (Agfa Corp.) followed by densitometry using NIH 
Image 1.61. 
 
Cytotoxicity assay 
Cell lines infected with each lentiviral shRNA pool were plated at a density of 4,000 
cells/well (45 µL) in 384-well plates (Corning #3712) and treated with vehicle (water), 
doxorubicin, daunorubicin, or epirubicin (Sigma) over 12 concentrations (four replicates for each 
dose).  Two cell lines were assayed per plate in the presence of 5µL of 10X [drug].  Seventy-two 
hours later, 5 µL Alamar Blue (Invitrogen) was added to each well and fluorescence values 
(excitation: 535 nm, emission: 595nm) were acquired using the Tecan 1000 Multiplate Reader 
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(Tecan) 24 hours later.  Three independent biological replicate experiments were performed, 
each with quadruplicate technical replicates for each experimental condition. 
 
Quality control pipeline 
The fluorescence data were processed through a quality control pipeline before being 
converted into percent cell viability at each drug concentration, per Equation 1 below.  Briefly, 
any plate whose 90th percentile was below 2000 relative fluorescence units (RFUs) was 
assumed to contain mostly dead cells, and was removed from subsequent analysis.  Next, 
positional effects (within a 2x12 group of 6 quadruplicate replicates, statistically significant 
(p<0.01) with effect sizes >1500 RFUs) were also examined.  Third, a coefficient of variation (CV) 
screen was performed.  If the CV >0.2, the deviate value was replaced with the mean of the 
other 3 non-deviant replicates.  Finally, special care was taken with the 10% dimethyl sulfoxide 
(DMSO, negative) and vehicle (positive) controls, given their significant impact in calculating % 
viability.  Mean viabilities from the 10% DMSO readings were checked to be within the 
biologically plausible range of 550 to 900 RFUs. The proportion of data affected by each step is 
given in Table 1. 
Table 1:  Proportion of Raw Data Affected by Each Quality Control Step 
 
The high-throughput format of the experimental system is robust, as evidenced by less than 5% total of the overall 
data subject to quality control correction measures. 
Step Proportion
1 0.021
2 0.012
3 0.013
4 0.000
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Percent viability was determined from each independent experiment per equation 1.  
Data were plotted and non-linear (Hill slope) curve fits were applied to generate dose-response 
graphs.  These graphs were utilized to generate IC50, Δ, and mean viability (AUC) values. 
 
Equation 1: 
% 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  𝑚𝑒𝑎𝑛 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑅𝐹𝑈 −𝑚𝑒𝑎𝑛 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑅𝐹𝑈
𝑚𝑒𝑎𝑛 𝑣𝑒ℎ𝑖𝑐𝑙𝑒 𝑅𝐹𝑈 −𝑚𝑒𝑎𝑛 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑅𝐹𝑈  
• Mean RFU (Relative Fluoresence Unit) values were derived from four wells. 
• 10% DMSO serves as a negative control against background fluorescence due to media 
or cellular debris.  Water served as vehicle for all drugs in this study. 
 
Statistical analysis methodology 
AUC responses were fit according to the linear mixed model in Equation 2, using SAS 9.2 
with the procedure “proc mixed".  The mixed models ANOVA is a generalization of the paired t-
test that allows us to model across all the drug and target gene knockdown conditions together.  
This enables a better estimate of the effect contributed by of each component, more precise 
estimates for the variance of residuals, and ultimately, an increase in statistical power. 
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Equation 2: 
𝐴𝑈𝐶𝑖𝑗𝑘𝑙𝑚 =  𝜇 + 𝑆𝑖 + 𝐶𝑖𝑗 + 𝐺𝑘 + 𝐷𝑙 + 𝑅𝑚 + 𝐺𝐷𝑘𝑙 + 𝑆𝐺𝑗𝑘 + 𝐶𝐷𝑖𝑗𝑙 + 𝐶𝐷𝑅𝑖𝑗𝑙𝑚 +∈𝑖𝑗𝑘𝑙𝑚 
• AUCijklm is the AUC for the jth cell line having sensitivity i, the kth gene target, the lth drug 
and the mth replicate.  
• Cell line is nested in sensitivity since each cell line has only one level of sensitivity, as 
opposed to the other factors, which are all crossed. 
• To account for their correlation between observations, cell line and replication were 
modeled as random effects 
• Sensitivity, Drug, and Gene effects were modeled as fixed effects. 
 
 
 
 
 
  
 CHAPTER 3 
RESULTS 
 
Genome-wide association analysis and candidate gene selection 
Prior to the work performed here, drug-dose phenotypes were established for over 500 
CHORI cell lines across the panel of 29 FDA-approved cytotoxic drugs as established in Peters et 
al. [36].  Genome-wide SNP profiles were also mapped for each cell line and nonparametric 
linkage analysis was utilized to identify genomic loci (“hits”) with putative correlation to 
variation in drug-dose response.  Figure 3 outlines a visual representation (Manhattan plot) of 
the association data for doxorubicin. 
With the large number of SNPs analyzed in a GWA study, hits are typically considered 
significant with p-values lower than 10-7.  As there were no results in this range for the initial 
screens of doxorubicin, epirubicin, and daunorubicin, a candidate list was built by identifying 
SNPs with the lowest p-values (ranging around 10-6) that were common to at least two of the 
three drugs screened.  The goal of this modified approach was to identify candidates that may 
affect the entire anthracycline drug class as opposed to a single member.   
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Figure 3: Doxorubicin GWAS 
The relative genome coordinate of each scanned SNP is located on the x-axis (left to right: Chromosome 1 through 
Chromosome 23) with the negative log of the statistical association p-value on the y-axis.  The greater the y-axis 
value, the stronger the association. 
 
 
In order to evaluate the shRNA-mediated gene knockdown approach, the candidate SNP list was 
further refined to a list of candidate genes.  None of the SNPs fell within the coding region of the 
genome, so the linkage disequilibrium (LD) of each SNP was examined through the the online 
SNAP (SNP Annotation and Proxy) tool available on the Broad Institute's website [37].  Based on 
this analysis, five candidate genes were selected (Table 2) for further validation.  TOP2A was also 
included as a positive control for its relevance to the anthracycline drug-class and lentivirus 
containing an empty shRNA plasmid was used as a negative control.  Finally, the phenotypic 
effect of each candidate gene knockdown was screened for each of the three anthracyclines. 
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 Table 2: Candidate Genes 
 
 
 
Selection of and generation of validation cell lines 
Little to no information is available on the functional impact of each SNP on its 
respective candidate gene, so we sought to identify a subset of CHORI cell lines suitable for use 
in the candidate gene validation.  As described in Brown et al. [38], various summary statistics 
are appropriate to describe drug dose-response.  We utilized the average viability statistic (the 
cell line-specific viability average at each tested drug concentration, approximately proportional 
to area under the curve [AUC]) using the phenotype data from the original screen to identify the 
sensitivity of all CHORI cell lines to each of the anthracyclines doxorubicin, daunorubicin, and 
epirubicin.  While IC50 is classically used to measure drug response, the viability statistic is also 
influenced by the shape of the hill slope curve and provides a more appropriate measure of 
response for our studies here.  As seen in Figure 4, the cell lines displayed a robust correlation in 
dose-response across all three drugs.  From the strength of these correlation data, the three 
most “sensitive” and “resistant” CHORI lines (Table 3) were selected and used for experiments 
with all three anthracycline drugs. 
 
Gene Official Name
TOP2A topoisomerase IIa
PELI2 pellino 2
FHIT fragile histidine triad
ADTRP androgen-dependent TFPI-regulating protein
CSMD3 CUB and Sushi multiple domains 3
SLC24A3 solute carrier family 24 (Na/K/Ca exchanger), member 3
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Table 3: Selected CHORI cell lines 
 
 
 
Figure 4: CHORI cell line selection 
A) Each dot corresponds to an individual cell line in the original screen, with the same 5 resistant and sensitive lines 
depicted in each comparative plot.  The cell lines were well correlated in response across all anthracyclines. 
   
         
  
Sensitive Resistant
032098 032174
031634 040722
30349 021783
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Figure 4: Continued 
B) A dose-response plot of a representative sensitive and resistant cell line depicts the nearly 0.75 log difference in 
IC50 these lines have to epirubicin. 
 
 
 
As described in the Materials and Methods section, lentivirus pools were made 
(negative control = empty virus, positive control = shTOP2A, and 5 experimental shRNAs) and 
introduced to each of the 6 cell lines selected for validation.  Of the 42 stable cell lines, three 
were unable to be established: 021784 shFHIT, 021784 shCSMD3, and 030349 shFHIT.  After 
selection and establishment of the stable knock-down cell lines (Figure 5), dose-response 
experiments were performed as in the initial screen.   
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Figure 5: Generation of Stable Cell Lines 
 
A) Infection of CHORI cells by lentivirus loaded with GFP expression plasmids indicates CHORI cells can be genetically 
manipulated, however at low efficiency.  Puromycin selection was used to establish stable cell line populations.   
B) Lysates from three cell lines (both shTOP2A and negative control) were probed for TOP2A protein expression three 
weeks after puromycin selection to demonstrate long-term, stable candidate gene knockdown.   
 
 
Results of Candidate Gene Validation  
Statistics (AUC, IC50, and Hill-slope, see Supplemental Tables 1-3) were generated for 
each cell line and the AUC statistics were fit to a linear mixed model per Equation 2 (Materials 
and Methods), from which two hypotheses were tested: 
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Hypothesis 1: Does gene knockdown affect viability in response to anthracycline exposure? 
In this model, a significant percentage of the AUC variability was explained by the gene 
target (Table 4).  After controlling for the effects of replicate, cell line, and drug treatment, PELI2 
(p<0.0014) and TOP2A (p<0.0006) (Figure 6) were significantly different in comparison to 
controls, with PELI2 knockdown conferring a sensitizing effect and TOP2A a resistance effect.  
Although not quite meeting the threshold of resistance, FHIT (p =0.0522) also had a sensitizing 
response.  Of the six cell lines screened in our validation study, generation of stable FHIT 
knockdown in 030349 (sensitive) and 021783 (resistant) cell lines was unsuccessful and may 
influence the FHIT result.   
 Table 4: Candidate Gene Knockdown p-values 
 
 The positive control TOP2A and candidate PELI2 were both shown to significantly affect anthracycline drug-dose 
response, with reduction of PELI2 sensitizing cells, and TOP2A knockdown causing resistance. 
 
shRNA P-value
ADTRP 0.0968
CSMD3 0.701
FHIT 0.0522
PELI2 0.0014
SLC24A3 0.2624
TOP2A 0.0006
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Figure 6: Effects of TOP2A and PELI2 reduction on drug dose-response  
 
 
TOP2A reduction served as a positive control in this study and authenticated the validation assay's ability to identify 
genetic loci important to anthracycline response.   shTOP2A cell lines (red) were approximate 1.75 fold more resistant 
(via IC50) to epirubicin than negative controls (black), a consistent effect across the drug class. 
ADTRP, CSMD3, FHIT, and SLC24A3 failed to validate in this study.  A representative dose-response plot is shown for 
SLC24A3.  In contrast, reduction of PELI2 sensitizes CHORI cells approximately 2X. 
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Hypothesis 2: Are viability effects consistent for the entire drug class versus a specific drug? 
 The model tested if the interaction between drug and gene target is significant.  A 
significant result would indicate that at least one drug responds significantly differently than the 
other two for at least one gene target.  The p-value for this result is not significant at 0.9809, 
signifying all gene knockdown associated variation seen was consistent across all three 
anthracyclines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER 4 
DISCUSSION 
 
The primary goal of these experiments was to validate hits arising from a 
pharmacogenomics screen employed to identify variant loci that affect anthracycline dose 
response.  As an important piece of this screening approach, these data are expected to yield 
new insight into biological mechanisms of anthracycline efficacy and/or identify potential 
genomic indicators of response and toxicity.  The findings indicate that 1) dose-response assays 
utilizing lentivirus to mediate shRNA gene knockdown are an effective validation strategy; 2) of 
the candidate genes tested, PELI2 (described further below) is the strongest candidate for 
further studies investigating its role in anthracycline response; and 3) average viability and AUC 
are valid statistics to measure drug response. 
 
Method Validation 
 While LCL-based, drug-dose phenotype assays are a useful tool for enabling clinically-
relevant SNP discovery, follow-up studies in relevant tissues and clinical cohorts are needed to 
validate their findings [3].  We’ve determined here that a) Epstein-Barr Virus-transformed LCLs 
can be transfected via shRNA-containing lentivirus to generate stable gene knock-down; and b) 
significant change in drug-dose response can be detected in these cell lines.  Utilizing this 
method as an intermediary validation step before continuing to clinical cohorts will prove useful. 
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Topoisomerase IIa is a well-established molecular target for anthracyclines [16, 17] and 
as such, TOP2A-deficient LCLs were generated and tested to determine if the dose-response 
assay could detect a phenotypic response.  As shown by statistically significant increase in AUC 
(p<0.0006, Supplemental Table 6), cells with reduction in TOP2A were more resistant to 
anthracyclines.  Interestingly, it has also been shown that drug-resistant tumors have similar 
changes in TOP2A protein levels [18].    
 
Candidate Gene Validation 
Of the five candidate genes examined, reduction of ADTRP, CSMD3, and SLC24A3 failed 
to show any significant cellular response to DNR, DOX, or EPI.  While little is known of their 
individual endogenous functions, it is interesting to consider CSMD3 was recently shown in a 
whole-exome sequencing analysis to be the second-most mutated gene in lung cancer behind 
TP53 [39].  Our results do not conclusively exempt the possible impact of these genes on cancer 
biology, but rather leave them open to future examination.  In conjunction with previous 
evidence, our data support a further investigation of the hits validated in this study.  
PELI2:  Studies have identified pellino 2, or PELI2, as an important signaling scaffold 
involved in IL-1-mediated activation of NF-ᴋβ [40].  PELI2 modulates NF-ᴋβ dynamics through its 
RING E3-ubiquitin-ligase activity [41] and has also been shown to activate MAPK pathways [42].  
A significant node in acquired chemotherapy-resistance [43, 44], NF-ᴋβ signaling mediates 
resistance to anthracyclines [45, 46] and has also been implicated in cardiotoxicity [47].   
 Our studies show knock-down of PELI2 confers anthracycline sensitivity (p<0.0014) and 
highlights the significance of NF-ᴋβ signaling in chemoresistance.  It should be noted that after 
development, PELI2 expression is restricted primarily to tissues involved in the innate immune 
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response [40] and may explain its demonstrable effect in our particular cell system.  Further 
studies examining PELI2 involvement in cancer-specific NF-ᴋβ activation may prove clinically 
relevant given many cancers are thought to undergo “dedifferentiation” [48].  The role of NF-ᴋβ 
inhibition in reducing both anthracycline-induced cardiotoxicity [47] and drug-resistance [44] 
lends considerable weight to further exploration of this pathway and its many regulatory 
modulators. 
FHIT:  FHIT reduction was seen to sensitize cells to anthracycline exposure, though our 
results were not statistically significant (p<0.522) and underpowered (n=4) when compared to 
the other candidate genes (n=6).  Regardless, it is interesting to note that FHIT is thought to be a 
tumor-suppressor and loss or aberrant expression is a hallmark of many cancers of the breast 
and lung [49].  Further studies with larger samples sizes will be important in determining if our 
tentative result is biologically relevant. 
 
Measuring drug ‘response’ 
 As the study of pharmacogenomics has broadened awareness of the impact of genetic 
variability, additional methods to describe and analyze drug response are needed.  Traditional 
summary measures, such as IC50 and hill slope, while convenient and straightforward, limit the 
assessment of all factors contributing to variability.  While methods continue to improve [38], 
the descriptions of and conclusions from complex datasets generated from these experimental 
approaches need to be carefully evaluated and results validated in other systems. 
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Conclusions 
 While investigated extensively for over fifty years, a detailed understanding of the 
mechanisms of anthracycline antineoplastic function and cardiotoxicity remain elusive.  Studies 
such as these exploit individual biological variation in efforts to identify novel genetic effectors.  
While our results implicate PELI2, the direct translational relevance of this finding is unclear.  
Further validation work will entail analysis in relevant cell and cancer model systems.  Additional 
studies may also include direct genomic examination of patient cohorts, as a similar approach 
undertaken with the TOP1 inhibitor, temozolomide, confirmed a direct clinical correlate [50].  
These steps to more fully understand how such variation affects human health will lead us closer 
toward the ambitious goal of “personalized medicine”. 
  
 APPENDIX 
 
Supplemental Table 1: 
AUC statistic, mean and standard deviation 
 
  
 
  
Table A: Daunorubicin
Control TOP2A PELII2 FHIT ADTRP CSMD3 SLC24A3
32098 10.9 +- 0.51 10.7 +- 0.39 10.6 +- 0.36 10.6 +- 0.44 10.9 +- 0.87 10.7 +- 0.47 10.7 +- 0.33
32174 11.5 +- 0.45 11.4 +- 0.098 11.2 +- 0.27 11.5 +- 0.31 11.6 +- 0.43 11.6 +- 0.5 11.5 +- 0.27
40722 11 +- 0.42 11.1 +- 0.42 11.3 +- 0.23 10.6 +- 0.078 11.4 +- 1.3 10.5 +- 0.32 10.7 +- 0.42
31634 10.9 +- 0.46 11.6 +- 0.23 11.2 +- 0.042 11.1 +- 0.068 11.1 +- 0.14 11.6 +- 0.21 11.1 +- 0.3
30349 10.7 +- 0.27 10.8 +- 0.57 10.2 +- 0.37 10.5 +- 0.86 10.6 +- 0.17 10.6 +- 0.48
21783 11.5 +- 0.42 11.8 +- 1.4 11.3 +- 0.81 11.6 +- 0.71 11.8 +- 0.61
Table B: Doxorubicin
Control TOP2A PELI2 FHIT ADTRP CSMD3 SLC24A3
32098 8.57 +- 0.81 8.7 +- 0.55 7.97 +- 0.77 8.14 +- 0.75 8.44 +- 0.92 8.38 +- 0.52 8.49 +- 0.81
32174 10.2 +- 0.76 10.4 +- 0.26 9.39 +- 0.58 10.2 +- 0.7 10.4 +- 0.87 10.4 +- 0.32 10.1 +- 0.67
40722 9.07 +- 0.37 8.78 +- 0.44 8.44 +- 0.19 8.21 +- 0.75 9.54 +- 1.3 8.13 +- 0.34 8.83 +- 0.38
31634 9.03 +- 0.63 10 +- 0.35 9.23 +- 0.52 9.18 +- 0.7 9.3 +- 0.64 9.87 +- 0.31 9.39 +- 0.7
30349 8.4 +- 0.65 8.78 +- 1.1 7.71 +- 1 8.56 +- 1.5 8.4 +- 0.64 8.58 +- 1.2
21783 10.4 +- 1 10.5 +- 1.8 9.88 +- 1.6 10.2 +- 1.8 10.6 +- 1.3
Table C: Epirubicin
Control TOP2A PELI2 FHIT ADTRP CSMD3 SLC24A3
32098 5.17 +- 0.54 5.13 +- 0.39 4.84 +- 0.42 4.79 +- 0.55 4.93 +- 0.55 4.98 +- 0.19 5.13 +- 0.49
32174 6.67 +- 0.51 6.99 +- 0.25 5.99 +- 0.59 6.51 +- 0.79 6.77 +- 0.97 6.59 +- 0.54 6.58 +- 0.65
40722 5.33 +- 0.56 5.35 +- 0.23 4.95 +- 0.32 4.99 +- 0.52 5.79 +- 1 4.98 +- 0.25 5.38 +- 0.11
31634 5.26 +- 0.36 5.93 +- 0.38 5.43 +- 0.4 5.31 +- 0.52 5.45 +- 0.48 5.95 +- 0.2 5.54 +- 0.42
30349 4.62 +- 0.97 5.18 +- 0.7 4.63 +- 0.62 5.12 +- 0.96 4.98 +- 0.35 5.08 +- 0.74
21783 7.18 +- 1.7 7.47 +- 2.1 6.7 +- 2.1 6.8 +- 2.2 7.4 +- 2.1
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Supplemental Table 2: 
log IC50 statistic, mean and standard deviation 
 
 
 
 
  
Table A: Daunorubicin
Control TOP2A PELI2 FHIT ADTRP CSMD3 SLC24A3
32098 -9.86 +- 0.095 -9.86 +- 0.12 -9.89 +- 0.047 -9.89 +- 0.1 -9.97 +- 0.1 -9.82 +- 0.17 -9.93 +- 0.049
32174 -9.49 +- 0.62 -10 +- 0.055 -9.06 +- 1.2 -9.56 +- 0.57 -9.97 +- 0.18 -9.81 +- 0.22 -9.82 +- 0.037
40722 -9.38 +- 0.84 -10 +- 0.2 -10.1 +- 0.12 -9.72 +- 0.37 -10 +- 0.15 -9.74 +- 0.28 -10 +- 0.051
31634 -9.84 +- 0.099 -10 +- 0.25 -10.1 +- 0.18 -9.78 +- 0.14 -10.2 +- 0.21 -9.95 +- 0.22 -9.85 +- 0.51
30349 -9.91 +- 0.093 -9.91 +- 0.12 -9.98 +- 0.11 -10 +- 0.086 -10 +- 0.13 -9.88 +- 0.052
21783 -9.83 +- 0.1 -9.81 +- 0.19 -11.2 +- 2.3 -13 +- 4.8 -8.88 +- 1.8
Table B: Doxorubicin
Control TOP2A PELI2 FHIT ADTRP CSMD3 SLC24A3
32098 -9.05 +- 0.48 -9.01 +- 0.18 -9.39 +- 0.34 -9.21 +- 0.31 -9.28 +- 0.32 -9.19 +- 0.16 -8.95 +- 0.49
32174 -8.61 +- 0.67 -7.84 +- 0.18 -9.35 +- 0.54 -7.6 +- 0.85 -9.01 +- 0.89 -8.48 +- 0.49 -8.41 +- 0.35
40722 -8.65 +- 0.095 -8.66 +- 0.17 -9.27 +- 0.28 -9.22 +- 0.57 -8.72 +- 0.33 -9.26 +- 0.015 -8.55 +- 0.081
31634 -8.61 +- 0.29 -8.17 +- 0.38 -8.51 +- 0.53 -8.54 +- 0.46 -8.51 +- 0.56 -8.24 +- 0.34 -8.33 +- 0.57
30349 -9.14 +- 0.56 -9.14 +- 0.73 -9.64 +- 0.68 -8.99 +- 0.83 -9.54 +- 0.29 -9.03 +- 0.77
21783 -8.04 +- 0.31 -8.7 +- 0.38 -9.38 +- 1.2 -10.7 +- 2.8 -8.67 +- 1.1
Table C: Epirubicin
Control TOP2A PELI2 FHIT ADTRP CSMD3 SLC24A3
32098 -9.42 +- 0.56 -9.29 +- 0.12 -9.53 +- 0.37 -9.55 +- 0.38 -9.6 +- 0.4 -9.36 +- 0.13 -9.39 +- 0.4
32174 -8.25 +- 0.64 -7.76 +- 0.14 -8.73 +- 0.82 -8.16 +- 0.54 -7.95 +- 0.55 -8.18 +- 0.5 -8.22 +- 0.5
40722 -8.71 +- 0.38 -8.81 +- 0.18 -9.8 +- 0.51 -9.44 +- 0.27 -8.67 +- 0.31 -9.58 +- 0.092 -8.67 +- 0.11
31634 -8.85 +- 0.2 -8.31 +- 0.19 -8.72 +- 0.54 -8.86 +- 0.39 -8.6 +- 0.46 -8.26 +- 0.18 -8.59 +- 0.3
30349 -9.19 +- 0.37 -9.33 +- 0.65 -9.87 +- 0.61 -9.18 +- 0.76 -9.72 +- 0.37 -9.46 +- 0.66
21783 -8.24 +- 0.73 -8.46 +- 0.95 -8.55 +- 1.1 -8.3 +- 1.1 -8.22 +- 0.78
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Supplemental Table 3: 
Hill-slope statistic, mean and standard deviation 
 
 
 
 
Table A: Daunorubicin
Control TOP2A PELI2 FHIT ADTRP CSMD3 SLC24A3
32098 -30 +- 8.2 -26.5 +- 4.9 -29.9 +- 8.8 -26.8 +- 3.7 -30.4 +- 0.86 -30.5 +- 6.7 -20.2 +- 2.1
32174 -26.6 +- 19 -25.6 +- 1.9 -12.6 +- 5.3 -16.4 +- 8.1 -32.5 +- 14 -24.7 +- 8.9 -22.7 +- 4.7
40722 -15 +- 8.4 -26.5 +- 7.3 -24.5 +- 12 -17.7 +- 2.2 -27.1 +- 18 -15.1 +- 5.6 -29.8 +- 9.7
31634 -29 +- 3.4 -27 +- 10 -34.2 +- 1.1 -19 +- 5.2 -23.7 +- 9.1 -28.5 +- 3.4 -17.7 +- 3.7
30349 -25.7 +- 6.7 -28.5 +- 4.8 -26.7 +- 8.9 -34.8 +- 10 -30.1 +- 2.4 -28.3 +- 9
21783 -18.6 +- 6.6 -16.6 +- 5.9 -9.99 +- 7.9 -8.37 +- 3 -15.8 +- 13
Table B: Doxorubicin
Control TOP2A PELI2 FHIT ADTRP CSMD3 SLC24A3
32098 -10.8 +- 2.1 -11.7 +- 1.9 -11.7 +- 0.84 -10.6 +- 1.8 -10.8 +- 1.8 -11.3 +- 1.2 -9.65 +- 0.73
32174 -8.56 +- 2.6 -6.27 +- 1.4 -7.54 +- 0.94 -5.73 +- 2.5 -7.97 +- 1.5 -7.67 +- 1.6 -9.56 +- 3.2
40722 -9.64 +- 1 -10.5 +- 0.45 -9.66 +- 1.5 -10.5 +- 1.2 -9.28 +- 1.4 -8.82 +- 0.97 -10.5 +- 1.2
31634 -10.4 +- 2 -10.7 +- 2.9 -8.72 +- 2.1 -9.48 +- 1.9 -9.18 +- 1.3 -9.1 +- 1.3 -8.25 +- 1.6
30349 -10.2 +- 2.9 -13 +- 2.3 -14.4 +- 6.6 -9.74 +- 2.2 -11.3 +- 2.1 -11.6 +- 2.8
21783 -7.31 +- 1.5 -11.2 +- 3.6 -8.36 +- 0.9 -6.16 +- 2.9 -6.46 +- 3.6
Table C: Epirubicin
Control TOP2A PELI2 FHIT ADTRP CSMD3 SLC24A3
32098 -12.8 +- 2 -12.9 +- 0.56 -13.3 +- 1.1 -11.6 +- 1 -11.3 +- 1.6 -11.5 +- 2.1 -13.1 +- 0.19
32174 -13.1 +- 3.4 -15.7 +- 11 -7.63 +- 0.96 -16.2 +- 4.7 -16.6 +- 6.4 -18.2 +- 12 -19 +- 9.6
40722 -17 +- 6.3 -12.7 +- 1.8 -10.7 +- 2.2 -11.8 +- 0.29 -12.4 +- 2.5 -9.92 +- 0.83 -12.1 +- 2.2
31634 -10.9 +- 0.44 -17 +- 3.2 -10.2 +- 2.8 -11 +- 1 -14.6 +- 6.9 -16.4 +- 4.7 -13.5 +- 6.4
30349 -17.1 +- 7.7 -13.7 +- 0.98 -12.6 +- 2.2 -11 +- 2 -11.3 +- 1.5 -13 +- 0.85
21783 -22 +- 15 -19.7 +- 13 -18.1 +- 8.7 -23.4 +- 16 -23.6 +- 9.1
 Supplemental Figure 1a: 
CHORI line 032098 
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Supplemental Figure 1b: 
CHORI line 032174 
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Supplemental Figure 1c: 
CHORI line 040722 
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Supplemental Figure 1d: 
CHORI line 031634 
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Supplemental Figure 1e: 
CHORI line 030349 
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Supplemental Figure 1f: 
CHORI line 021784 
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